Navigation Links
Anti-TNF Golimumab Continues to Show Promise in Phase II Rheumatoid,Arthritis Study

Golimumab Demonstrated Sustained Improvement in Signs and Symptoms Of Moderate to Severe Rheumatoid Arthritis With One-Third of Patients Achieving Disease Remission at One-Year Mark

BARCELONA, Spain, 14 June 2007 – One-year data show nearly 75 percent of patients with moderate to severe rheumatoid arthritis (RA) receiving golimumab (CNTO 148) and methotrexate (MTX) experienced and maintained at least 20 percent improvement in arthritis symptoms (ACR 20). This was according to findings from a double-blind, placebo-controlled, dose-ranging Phase II study presented today at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology. The same study also showed that, on average, more than one-third of these patients achieved disease remission at one year as evaluated by Disease Activity Score 28 (DAS28) [DAS < 2.6].

Golimumab is a fully-human anti-TNF-alpha monoclonal antibody that targets and neutralizes both the soluble and the membrane-bound form of TNF-alpha. Developed by Centocor, Inc and Schering-Plough Corporation (NYSE: SGP), golimumab is being investigated for administration by both subcutaneous (SC) injection and intravenous (IV) infusion.

“The maintained therapeutic effect demonstrated by these results is very promising,” said Iain B. McInnes, FRCP, Ph.D., Professor of Experimental Medicine at the University of Glasgow; Honorary Consultant Rheumatologist, Centre for Rheumatic Diseases, Glasgow Royal Infirmary in Glasgow, United Kingdom, who serves as a lead investigator in a Phase III study of golimumab. “Physicians treating patients with RA are always looking for advanced medications that offer sustained efficacy to keep this serious, life-altering condition in remission.”

Data from the study showed that significantly greater percentages of patients treated with golimumab plus MTX achieved ACR 20, 50 and 70 responses (mark
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
2. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
3. New Drugs in Multinational Study Show Promise in Fighting Drug-Resistant HIV
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
6. Trial Results with Intranasal Fentanyl Hold Promise for Treatment of Breakthrough Pain in Cancer
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
9. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
10. Alzheimers Drug Shows Promise in Fighting Cancer
11. Data on Telavancin and Micafungin Hold Promise of New Therapeutic Options in Fight Against Serious Infectious Disease
Post Your Comments:
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
(Date:8/31/2015)... 2015  The departments of Drug and Alcohol Programs ... Concept 90 to raise awareness for International Overdose Awareness ... Pennsylvania and help more Pennsylvanians with ... through the Building Bridges to Recovery initiative. ... day to a disease that is fully treatable, if ...
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... With former ... Engineering and Math) disciplines since its inception more than 35 years ago. A pilot ... students and their teachers - and, not just those intent on pursuing careers in ...
(Date:9/1/2015)... ... September 01, 2015 , ... WorkCare, Inc., a ... its medical management team as an Associate Medical Director. , WorkCare specializes ... in the U.S. and abroad. , Dr. Nelson has a diverse background. ...
(Date:9/1/2015)... Switzerland (PRWEB) , ... September 01, 2015 , ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , featuring ... presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , Calibration, ...
(Date:9/1/2015)... ... , ... Ogawa’s new massage chairs tout innovative functionality that change the way ... before. With the goal of bringing wellness to the world, Ogawa introduces their new ... As in its name, the Ogawa Refresh aims to “refresh” and rejuvenate ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... is, how to access caregivers and what to look for and expect when ... information. , Founded in 2006 in Canoga Park, CA by CEO, Richard Weatherman ...
Breaking Medicine News(10 mins):Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:AdvantagePlusCaregivers.com® Launches New Website for Corporate and Franchisee Locations in 3 States 2
... ... Award. , ... March 30, 2010 -- Five Summit Medical Group physicians have recently received the MDX/American ... M.D., Eric Mrisky, M.D., and Monib Zirvi, M.D., join their colleagues, Lisa M. Coohill, ...
... about proper use of antibiotics have the potential to ... to a report in the April issue of ... publication of the Association for Professionals in Infection Control ... MixedInk (New York, NY) studied the health information content ...
... to health with shelter dogs , TUESDAY, March 30 (HealthDay ... "leash" on life as they gain strength by walking dogs ... Cardiac Friends, is a partnership between ProHealth Care (PHC) and ... , "It,s a great way to help the dogs and ...
... Aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs ... symptoms of arthritis and other inflammatory disorders. But ... have osteoarthritis) these medications are also known to ... body, particularly in the gastrointestinal tract. ...
... ... , ... -- SDI , a leading healthcare market insight and analytics firm, today reported that ... 6% in 2009 compared to 2008. The growth rate of all inpatient hospital stays that ...
... ... therapy is a major key for returning us back to our natural state as a ... ... Integrative Medicine and an Industrial Toxicologist, has dedicated a quarter of a century to discovering ...
Cached Medicine News:Health News:Summit Medical Group Physicians Receive Patients' Choice Award 2Health News:Summit Medical Group Physicians Receive Patients' Choice Award 3Health News:Misinformation about antibiotics can travel to large audience via Twitter: study 2Health News:Misinformation about antibiotics can travel to large audience via Twitter: study 3Health News:Man's Best Friend Helps Mend Broken Hearts 2Health News:Man's Best Friend Helps Mend Broken Hearts 3Health News:McMaster researcher leads development of promising drug for inflammation 2Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 2Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 3
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
Saline Solution to rinse and store soft contact lenses and for heat disinfection....
Sensitive Eyes Plus Saline Solution to rinse soft contact lenses The unique, gentle, pH-balanced formula contains potassium, an ingredient found in tears....
Medicine Products: